The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Allergan Medical Identifier:
First received: December 7, 2010
Last updated: June 18, 2013
Last verified: June 2013

The purpose of the study is to obtain clinical experience with the use of SERI® Surgical Scaffold for tissue support and repair in breast reconstruction.

Condition Intervention
Breast Reconstruction
Device: SERI® Surgical Scaffold

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan Medical:

Primary Outcome Measures:
  • Investigator satisfaction following use of SERI® Surgical Scaffold evaluated using an 11-point scale questionnaire [ Time Frame: 6 months after stage I surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Investigator satisfaction assessment at other timepoints evaluated using an 11-point scale questionnaire [ Time Frame: Immediately after stage II surgery, and 12, 18 and 24 months after stage I surgery ] [ Designated as safety issue: No ]
  • SERI® Surgical Scaffold Investigator Ease of Use assessment [ Time Frame: Following Stage I surgery ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: October 2010
Estimated Study Completion Date: October 2014
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Breast Reconstruction
Device: SERI® Surgical Scaffold
Breast reconstruction surgery


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To be eligible for enrollment, the subject must:

  • Be female, greater or equal to 18 years of age
  • Be willing to undergo breast reconstruction with sub-pectoralis muscle placement of a tissue expander, followed by exchange with a sub-pectoral breast implant
  • Have previously had or be willing to undergo mastectomy with healthy, well-vascularized skin flaps anticipated by the surgeon
  • Be in good health other than breast pathology and be suited to general anesthesia and planned treatments

Exclusion Criteria:

The subject must not:

  • Have undergone breast radiation treatment and/or is preoperatively evaluated to require radiation treatment to the breast area during the course of the study
  • Have a known allergy to silk
  • Have collagen-vascular, connective disease, or bleeding disorders
  • Have a BMI that is greater than or equal to 35
  • Have any disease, including uncontrolled diabetes, which is clinically known to impact wound healing ability
  • Have an autoimmune disease, an immune deficiency, or is on immune suppression drugs other than any other current treatment for breast cancer
  • Have smoked within the last 12 months
  • Currently have an alcohol/substance abuse problem or have had a relapse within 1 year prior to screening visit
  • Be pregnant, lactating, or expecting to be within the next 24 months
  • Have concomitant unrelated condition of breast/chest wall/skin
  • Have an abscess or infection at the time of surgery
  • Have undergone previous breast surgery with the exception of mastectomy, breast biopsy, cyst removal, lumpectomy, mastopexy, reduction and/or augmentation
  • Have had a prior soft tissue support device implanted in the breast
  • Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  Contacts and Locations
Please refer to this study by its identifier: NCT01256502

United States, California
Los Angeles, California, United States
Sponsors and Collaborators
Allergan Medical
  More Information

No publications provided

Responsible Party: Allergan Medical Identifier: NCT01256502     History of Changes
Other Study ID Numbers: SURE-001
Study First Received: December 7, 2010
Last Updated: June 18, 2013
Health Authority: United States: Food and Drug Administration processed this record on April 17, 2014